株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

パーキンソン病:市場予測と分析

Parkinson's disease forecast and market analysis to 2035

発行 Datamonitor Healthcare 商品コード 365210
出版日 ページ情報 英文 299 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.66円で換算しております。
Back to Top
パーキンソン病:市場予測と分析 Parkinson's disease forecast and market analysis to 2035
出版日: 2017年03月03日 ページ情報: 英文 299 Pages
概要

当レポートでは、パーキンソン病治療薬市場について調査分析し、市場予測、治療、疫学、上市薬、パイプライン薬の動向など、体系的な情報を提供しています。

予測:パーキンソン病

  • エグゼクティブサマリー
  • 市場概要・動向
  • 市場定義・調査手法
  • Azilect (rasagiline)
  • CVT-301
  • Duopa (levodopa/carbidopa)
  • Neupro (rotigotine)
  • Nouriast (istradefylline)
  • Rytary (carbidopa/levodopa)
  • Stalevo (carbidopa/levodopa/entacapone)
  • tozadenant
  • Xadago (safinamide)
  • 1次調査手法

治療:パーキンソン病

  • エグゼクティブサマリー
  • 1次調査手法
  • 疾患の定義・診断
  • 患者区分
  • 現在の治療オプション
  • 処方動向
  • アンメットニーズ

疫学:パーキンソン病

  • エグゼクティブサマリー
  • 疾患の背景
  • 情報源・手法
  • 予測
  • 疫学者の考察
  • 強みと限界

上市薬:パーキンソン病

  • エグゼクティブサマリー
  • 付録
  • 製品プロファイル:Apokyn
  • 製品プロファイル:Azilect
  • 製品プロファイル:Duopa
  • 製品プロファイル:Mirapex ER
  • 製品プロファイル:Neupro
  • 製品プロファイル:Nouriast
  • 製品プロファイル:Rytary
  • 製品プロファイル:Stalevo
  • 製品プロファイル:Zelapar

パイプライン:パーキンソン病

  • エグゼクティブサマリー
  • 臨床パイプライン概要
  • 初期段階の機会
  • 最新のアナリストの見解
  • 付録
  • 製品プロファイル (後期段階) :CVT-301
  • 製品プロファイル (後期段階) :Xadago
  • 製品プロファイル (後期段階) :tozadenant

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: DMKC4850

Sizable pipeline characterized by both high growth and attrition

Parkinson's disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Patients also experience significant non-motor symptoms including changes in cognition and mood, sleep disturbances, and autonomic dysfunction. The condition is caused by the degeneration of dopamine-producing cells of the substantia nigra. Parkinson's disease is incurable, but non-fatal, resulting in poor quality of life and increasing disability as the disease progresses. Studies classify Parkinson's disease as the second most common neurologic disease following Alzheimer's disease, and it is expected to cause an increasing social and economic burden as populations age.

Recent events and opinion

Parkinson's disease is predominantly treated with longstanding and mature therapies such as levodopa and the dopamine agonists, pramipexole and ropinirole. The market is therefore dominated by generics, with Teva's Azilect (rasagiline) being the last lucrative drug indicated for all Parkinson's disease patients.

Drug developers have responded by introducing new treatment options with clearly defined positions in the market, typically as an option for reducing motor fluctuations alongside levodopa therapy.

The Parkinson's disease pipeline is characterized by a high level of both growth and attrition. The vast majority of Parkinson's disease pipeline candidates are in the preclinical stages of development, however, many programs fail to progress into later stages.

Future clinical trials should aim to target a defined patient population. Clinical trials face difficulties including a high placebo response and poor recruitment of patients. The long duration and slow progressive course of the disease are key factors resulting in clinical trials requiring an extensive amount of resources.

Table of Contents

FORECAST: PARKINSON'S DISEASE

  • Executive Summary
  • Market Overview and Trends
  • Market Definition and Methodology
  • Azilect (rasagiline)
  • CVT-301
  • Duopa (levodopa/carbidopa)
  • Neupro (rotigotine)
  • Nouriast (istradefylline)
  • Rytary (carbidopa/levodopa)
  • Stalevo (carbidopa/levodopa/entacapone)
  • tozadenant
  • Xadago (safinamide)
  • Primary Research Methodology

TREATMENT: PARKINSON'S DISEASE

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends
  • Unmet Needs in Parkinson's Disease

EPIDEMIOLOGY: PARKINSON'S DISEASE

  • Executive Summary
  • Disease Background
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations

MARKETED DRUGS: PARKINSON'S DISEASE

  • Executive Summary
  • Appendix
  • Product profile: Apokyn
  • Product profile: Azilect
  • Product profile: Duopa
  • Product profile: Mirapex ER
  • Product profile: Neupro
  • Product profile: Nouriast
  • Product profile: Rytary
  • Product profile: Stalevo
  • Product profile: Zelapar

PIPELINE: PARKINSON'S DISEASE

  • Executive Summary
  • Clinical Pipeline Overview
  • Early-Phase Opportunities
  • Latest Analyst Opinion
  • Appendix
  • Product profile (late stage): CVT-301
  • Product profile (late stage): Xadago
  • Product profile (late stage): tozadenant

APPENDIX

  • Appendix: Epidemiology: Parkinson's Disease

LIST OF FIGURES

  • Figure 1: Parkinson's disease market sales value in the US, Japan, and five major EU markets ($m), 2014-23
  • Figure 2: Growth dynamics of the Parkinson's disease market in the US, Japan, and five major EU markets, 2014-23
  • Figure 3: Parkinson's disease market sales value in the US, Japan, and five major EU markets, by class ($m), 2014-23
  • Figure 4: Parkinson's disease market sales value in the US, Japan, and five major EU markets, by setting ($m), 2014-23
  • Figure 5: Leading Parkinson's disease brands in the US, Japan, and five major EU markets, by sales ($m), 2014-23
  • Figure 6: Patient-based forecast methodology for Parkinson's disease
  • Figure 7: Azilect sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 8: CVT-301 sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 9: Duopa sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 10: Neupro sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 11: Nouriast sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 12: Rytary sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 13: Stalevo sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 14: Tozadenant sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 15: Xadago sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 16: UK Parkinson's Disease Society Brain Bank criteria
  • Figure 17: Parkinson's disease diagnosis rates across the US, Japan, and five major EU markets, by country
  • Figure 18: Parkinson's disease progression
  • Figure 19: Segmentation of respondents' Parkinson's disease patients by disease stage in the US, Japan, and five major EU markets, by country
  • Figure 20: Early-stage Parkinson's disease patients who fall into each treatment category in the US, Japan, and five major EU markets, by country
  • Figure 21: Late-stage Parkinson's disease patients who fall into each treatment category in the US, Japan, and five major EU markets, by country
  • Figure 22: Mean percentage of patients with early-stage Parkinson's disease receiving each line of therapy, by country
  • Figure 23: Top five molecules prescribed for first-line treatment of early-stage Parkinson's disease, by country
  • Figure 24: Top five molecules prescribed for second-line and beyond treatment of early-stage Parkinson's disease, by country
  • Figure 25: Mean percentage of patients with late-stage Parkinson's disease receiving each line of therapy across the US, Japan, and five major EU markets, by country
  • Figure 26: Top five molecules prescribed for first-line treatment of late-stage Parkinson's disease, by country
  • Figure 27: Top five molecules prescribed for second-line and beyond treatment of late-stage Parkinson's disease, by country
  • Figure 28: Average compliance rates with Parkinson's disease therapies across the US, Japan, and five major EU markets, by disease subtype and administration route
  • Figure 29: Key unmet needs in Parkinson's disease across the US, Japan, and five major EU markets
  • Figure 30: Trend in diagnosed prevalent cases of Parkinson's disease in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 31: Absolute growth in diagnosed prevalent cases of Parkinson's disease in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 32: Age group-specific growth in diagnosed prevalent cases of Parkinson's disease in the US, Japan, and five major EU markets, 2015-35
  • Figure 33: Apokyn (apomorphine; Britannia Pharmaceuticals/Kyowa Hakko Kirin) SWOT analysis in Parkinson's disease
  • Figure 34: Datamonitor Healthcare's drug assessment summary for Apokyn in Parkinson's disease
  • Figure 35: Datamonitor Healthcare's drug assessment summary for Apokyn in Parkinson's disease
  • Figure 36: Azilect (rasagiline; Teva/Lundbeck/Takeda) SWOT analysis in Parkinson's disease
  • Figure 37: Datamonitor Healthcare's drug assessment summary for Azilect in Parkinson's disease
  • Figure 38: Datamonitor Healthcare's drug assessment summary for Azilect in Parkinson's disease
  • Figure 39: Duopa (carbidopa/levodopa intestinal gel; AbbVie) SWOT analysis in Parkinson's disease
  • Figure 40: Datamonitor Healthcare's drug assessment summary for Duopa in Parkinson's disease
  • Figure 41: Datamonitor Healthcare's drug assessment summary for Duopa in Parkinson's disease
  • Figure 42: Mirapex ER (pramipexole; Boehringer Ingelheim) SWOT analysis in Parkinson's disease
  • Figure 43: Datamonitor Healthcare's drug assessment summary for Mirapex ER in Parkinson's disease
  • Figure 44: Datamonitor Healthcare's drug assessment summary for Mirapex ER in Parkinson's disease
  • Figure 45: Neupro (rotigotine; UCB/Otsuka) SWOT analysis in Parkinson's disease
  • Figure 46: Datamonitor Healthcare's drug assessment summary for Neupro in Parkinson's disease
  • Figure 47: Datamonitor Healthcare's drug assessment summary for Neupro in Parkinson's disease
  • Figure 48: Nouriast (istradefylline; Kyowa Hakko Kirin) SWOT analysis in Parkinson's disease
  • Figure 49: Datamonitor Healthcare's drug assessment summary for Nouriast in Parkinson's disease
  • Figure 50: Datamonitor Healthcare's drug assessment summary for Nouriast in Parkinson's disease
  • Figure 51: Rytary (carbidopa/levodopa; Impax Laboratories) SWOT analysis in Parkinson's disease
  • Figure 52: Datamonitor Healthcare's drug assessment summary for Rytary in Parkinson's disease
  • Figure 53: Datamonitor Healthcare's drug assessment summary for Rytary in Parkinson's disease
  • Figure 54: Stalevo (carbidopa/levodopa/entacapone; Novartis/Orion) SWOT analysis in Parkinson's disease
  • Figure 55: Datamonitor Healthcare's drug assessment summary for Stalevo in Parkinson's disease
  • Figure 56: Datamonitor Healthcare's drug assessment summary for Stalevo in Parkinson's disease
  • Figure 57: Zelapar (selegiline; Valeant) SWOT analysis in Parkinson's disease
  • Figure 58: Datamonitor Healthcare's drug assessment summary for Zelapar in Parkinson's disease
  • Figure 59: Datamonitor Healthcare's drug assessment summary for Zelapar in Parkinson's disease
  • Figure 60: Dopamine signaling - SWOT analysis in Parkinson's disease
  • Figure 61: Adenosine A2a receptor antagonists - SWOT analysis in Parkinson's disease
  • Figure 62: Alpha-synuclein antibodies - SWOT analysis in Parkinson's disease
  • Figure 63: Platelet-derived growth factor pathway - SWOT analysis in Parkinson's disease
  • Figure 64: CVT-301 (levodopa; Acorda Therapeutics) SWOT analysis in Parkinson's disease
  • Figure 65: Datamonitor Healthcare's drug assessment summary for CVT-301 in Parkinson's disease
  • Figure 66: Datamonitor Healthcare's drug assessment summary for CVT-301 in Parkinson's disease
  • Figure 67: Xadago (safinamide; Newron Pharmaceuticals/Zambon/Meiji Seika Pharma) SWOT analysis in Parkinson's disease
  • Figure 68: Datamonitor Healthcare's drug assessment summary for Xadago in Parkinson's disease
  • Figure 69: Datamonitor Healthcare's drug assessment summary for Xadago in Parkinson's disease
  • Figure 70: Tozadenant (Biotie Therapies) SWOT analysis in Parkinson's disease
  • Figure 71: Datamonitor Healthcare's drug assessment summary for tozadenant in Parkinson's disease
  • Figure 72: Datamonitor Healthcare's drug assessment summary for tozadenant in Parkinson's disease

LIST OF TABLES

  • Table 1: Parkinson's disease market sales value in the US, Japan, and five major EU markets ($m), 2014-23
  • Table 2: Parkinson's disease market sales value in the US, Japan, and five major EU markets, by class ($m), 2014-23
  • Table 3: Parkinson's disease market sales value in the US, Japan, and five major EU markets, by setting ($m), 2014-23
  • Table 4: Price sources and calculations, by country
  • Table 5: Exchange rates used for calculating prices
  • Table 6: Estimated loss of exclusivity dates of key brands in Parkinson's disease in the US, Japan, and five major EU markets, 2014-23
  • Table 7: Estimated launch dates of key late-stage pipeline and marketed products in Parkinson's disease in the US, Japan, and five major EU markets, 2014-23
  • Table 8: Azilect sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 9: CVT-301 sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 10: Duopa sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 11: Neupro sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 12: Nouriast sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 13: Rytary sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 14: Stalevo sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 15: Tozadenant sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m),2014-23
  • Table 16: Xadago sales forecast for Parkinson's disease in the US, Japan, and five major EU markets, by country ($m),2014-23
  • Table 17: Neurologists surveyed for the Parkinson's disease primary research study, 2014
  • Table 18: Therapies discussed in the Parkinson's disease key opinion leader primary research study, 2014
  • Table 19: Neurologists and geriatricians surveyed for the Parkinson's disease primary research study, 2016
  • Table 20: Classification of Parkinson's disease severity according to original five-stage Hoehn and Yahr disability scale
  • Table 21: Symptoms of Parkinson's disease
  • Table 22: Major approved treatments available for Parkinson's disease across the US, Japan, and five major EU markets
  • Table 23: Summary of treatment guideline recommendations for the use of varying drug classes for early- and late-stageParkinson's disease
  • Table 24: Parkinson's disease patients treated with disease-modifying therapy in the US, Japan, and five major EU markets, bycountry (%)
  • Table 25: Top 10 regimens prescribed for first-line treatment of early-stage Parkinson's disease, by country (%)
  • Table 26: Top 10 regimens prescribed for second-line and beyond treatment of early-stage Parkinson's disease, by country(%)
  • Table 27: Top 10 regimens prescribed for first-line treatment of late-stage Parkinson's disease, by country (%)
  • Table 28: Top 10 regimens prescribed for second-line and beyond treatment of late-stage Parkinson's disease, by country(%)
  • Table 29: Recent high-profile clinical trial failures for the development of neuroprotective therapies in Parkinson's disease
  • Table 30: Side effects of commonly used medications in Parkinson's disease
  • Table 31: Sources used for Parkinson's disease analysis in the US, Japan, and five major EU markets
  • Table 32: Notable sources not used for Parkinson's disease analysis in the US, Japan, and five major EU markets
  • Table 33: Comparison of the original and currently used Hoehn and Yahr scales
  • Table 34: Sources used for estimating Hoehn and Yahr stage distributions in Parkinson's disease in the US, Japan, and fivemajor EU markets
  • Table 35: Sources used for estimating the prevalence of co-morbidities in Parkinson's disease in the US, Japan, and five majorEU markets
  • Table 36: Diagnosed prevalent cases of Parkinson's disease in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 37: Age-specific diagnosed prevalent cases of Parkinson's disease in the US, Japan, and five major EU markets, bycountry, 2015
  • Table 38: Gender-specific diagnosed prevalent cases of Parkinson's disease in the US, Japan, and five major EU markets, bycountry, 2015
  • Table 39: Hoehn and Yahr stage distribution of Parkinson's disease in the US, Japan, and five major EU markets, 2015
  • Table 40: Diagnosed prevalent cases of Parkinson's disease in the US, Japan, and five major EU markets, by Hoehn and Yahrstage, 2015
  • Table 41: Prevalence of co-morbidities in Parkinson's disease in the US, Japan, and five major EU markets, by co-morbidity,2015
  • Table 42: Diagnosed prevalent cases of Parkinson's disease in the US, Japan, and five major EU markets, by co-morbidity,2015
  • Table 43: Apokyn (apomorphine; Britannia Pharmaceuticals/Kyowa Hakko Kirin) - drug profile
  • Table 44: Pivotal Phase III clinical trial data for Apokyn (apomorphine; Britannia Pharmaceuticals/Kyowa Hakko Kirin) in Parkinson's disease
  • Table 45: Azilect (rasagiline; Teva/Lundbeck/Takeda) - drug profile
  • Table 46: Pivotal Phase III clinical trial data for Azilect (rasagiline; Teva/Lundbeck/Takeda) in Parkinson's disease
  • Table 47: Duopa (carbidopa/levodopa intestinal gel; AbbVie) - drug profile
  • Table 48: Pivotal Phase III clinical trial data for Duopa (carbidopa/levodopa intestinal gel; AbbVie) in Parkinson's disease
  • Table 49: Mirapex ER (pramipexole; Boehringer Ingelheim) - drug profile
  • Table 50: Pivotal Phase III clinical trial data for Mirapex ER (pramipexole; Boehringer Ingelheim) in Parkinson's disease
  • Table 51: Neupro (rotigotine; UCB/Otsuka) - drug profile
  • Table 52: Pivotal Phase III clinical trial data for Neupro (rotigotine; UCB/Otsuka) in Parkinson's disease
  • Table 53: Nouriast (istradefylline; Kyowa Hakko Kirin) - drug profile
  • Table 54: Pivotal Phase III clinical trial data for Nouriast (istradefylline; Kyowa Hakko Kirin) in Parkinson's disease
  • Table 55: Rytary (carbidopa/levodopa; Impax Laboratories) - drug profile
  • Table 56: Pivotal Phase III clinical trial data for Rytary (carbidopa/levodopa; Impax Laboratories) in Parkinson's disease
  • Table 57: Stalevo (carbidopa/levodopa/entacapone; Novartis/Orion) - drug profile
  • Table 58: Pivotal Phase III clinical trial data for Stalevo (carbidopa/levodopa/entacapone; Novartis/Orion) in Parkinson's disease
  • Table 59: Zelapar (selegiline; Valeant) - drug profile
  • Table 60: Pivotal Phase III clinical trial data for Zelapar (selegiline; Valeant) in Parkinson's disease
  • Table 61: Late-stage pipeline candidates under development for Parkinson's disease
  • Table 62: Select drugs in early-stage development for Parkinson's disease
  • Table 63: CVT-301 safety data in Parkinson's disease from the Phase III SPAN-PD trial
  • Table 64: CVT-301 (levodopa; Acorda Therapeutics) - drug profile
  • Table 65: Late-stage clinical trial development for CVT-301 (levodopa; Acorda Therapeutics) in Parkinson's disease
  • Table 66: Safinamide (Newron Pharmaceuticals/Zambon/Meiji Seika Pharma) - drug profile
  • Table 67: Late-stage clinical trial development for Xadago (safinamide; Newron Pharmaceuticals/Zambon/Meiji Seika Pharma) in Parkinson's disease
  • Table 68: Tozadenant (Biotie Therapies) - drug profile
  • Table 69: Efficacy data from Biotie's Phase II trial of tozadenant in Parkinson's disease
  • Table 70: Safety data from Biotie's Phase II trial of tozadenant in Parkinson's disease
  • Table 71: UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria
Back to Top